Fig. 2From: Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patientsChange in (A) MMD and (B) WMD in EM patients. Change in MMD represents mean change from baseline during the 4-week period from the first dose (ANCOVA analysis) while change in WMD represents mean change per week during the 4-week period from the first dose (MMRM analysis). An asterisk denotes Pā<ā0.05 and a dagger Pā<ā0.0001 for the comparison with placebo. Abbreviations: ANCOVA, analysis of covariance; LSM, least-squares mean; MMD, monthly migraine days; MMRM, mixed-effects model for repeated measures; WMD, weekly migraine daysBack to article page